This article explores the efficacy of CCC-h1005, a TPP-conjugated pyrrole-imidazole polyamide, in targeting a common mtDNA cancer risk variant in cervical cancer cells. CCC-h1005 induced cell death, inhibited tumor growth, and holds promise as a potential treatment for cervical cancer and other cancers with high copies of the target variant.
PrimeSurface 96-well U bottom ultra low attachment plates (MS-9096UZ) were used for spheroid formation.
